Article
Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Melanoma research - 1 Oct 2014
Rapisuwon Suthee, Parks Kellie, Al-Refaie Waddah, Atkins Michael B
Abstract excerpt
Primary mucosal melanomas represent ∼1.3% of all cases of melanoma diagnosed in the USA. The sinonasal location is the most common primary site. Mutations in the KIT gene occur in 10-22% of mucosal melanomas. Tumor response to imatinib mesylate has been reported in about half of the patients with tumors harboring KIT mutations. Responses are almost exclusively restricted to tumors with mutations in KIT exon 9 or...
Topics
- Antineoplastic Agents
- Benzamides
- Biopsy
- DNA Mutational Analysis
- Exons
- Fatal Outcome
- Female
- Humans
- Imatinib Mesylate
- Melanoma
- Middle Aged
- Mucous Membrane